February 13, 2017 01:10 PM ESTUpdated February 14, 08:31 AM

Marathon CEO tries to call a time out on controversy as lawmakers rip into $89K deflazacort price

John Carroll

Editor & Founder

Senator Bernie Sanders and Congressman Elijah Cummings have found their new poster boy for pharma price gouging. His name is Jeff Aronin, the CEO of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Marathon CEO tries to call a time out on controversy as lawmakers rip into $89K deflazacort price

John Carroll

Editor & Founder

Sign up to read this article for free.

The election is Tuesday. What’s at stake for the pharma industry?

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Is there room for MASH drugs in a GLP-1 world?

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Marathon CEO tries to call a time out on con­tro­ver­sy as law­mak­ers rip in­to $89K de­flaza­cort price

John Carroll

Editor & Founder

Sign up to read this article for free.

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

Is there room for MASH drugs in a GLP-1 world?

FDA cites Mark Cuban's drug com­pound­ing cen­ter in Dal­las with steril­i­ty, qual­i­ty con­cerns

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Marathon CEO tries to call a time out on controversy as lawmakers rip into $89K deflazacort price

The election is Tuesday. What’s at stake for the pharma industry?

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks